EHA 2023 | Challenges in treating patients with TP53-mutated MCL & promising novel therapies being explored
Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, discusses challenges in treating patients with TP53-mutated mantle cell lymphoma (MCL), emphasizing the poor outcomes demonstrated with current treatment approaches including chemoimmunotherapy (CIT), stem cell transplant (SCT), and Bruton’s tyrosine kinase (BTK) inhibitors. Dr Minson further comments on strategies being explored to improve outcomes for patients, and discusses the promise of novel immunotherapies, including bispecific antibodies and CAR-T cells. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Novartis, Roche, AbbVie
Travel funding: Novartis.
